Fig. 1: Epigenetic target structures and inhibitor classes.

Current clinical development including DNA-Methylation Inhibitors, Menin-/Dot1L-Inhibitors, BET-Inhibitors, HDAC-Inhibitors, LSD1/PRMT5-Inhibitors and indirect effects of JAK-Inhibitor treatment.